Dianthus Therapeutics Inc DNTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $88.05
- Day Range
- $87.22–91.04
- 52-Week Range
- $32.22–117.88
- Bid/Ask
- $36.26 / $135.00
- Shares Outstanding
- 55.93M
- Market Cap
- $4.94B
- Volume/Avg
- 767,034 / 832,343
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,168.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 92
- Website
- https://www.dianthustx.com
Valuation
|
Metric
|
DNTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.13 |
Price/Sales | 2,168.16 |
Price/Cash Flow | — |
Price/Earnings
DNTH
Financial Strength
|
Metric
|
DNTH
|
|---|---|
Quick Ratio | 25.79 |
Current Ratio | 26.10 |
Interest Coverage | — |
Quick Ratio
DNTH
Profitability
|
Metric
|
DNTH
|
|---|---|
Return on Assets (Normalized) | −20.32% |
Return on Equity (Normalized) | −21.29% |
Return on Invested Capital (Normalized) | −24.84% |
Return on Assets
DNTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!%?b&% | LOCK|!^j>> | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H@lVVx% | LOCK|^Dq^! | $76B | |||
| Moderna Inc
MRNA
| LOCK|LqyrzF | LOCK|s^S | $75B | |||
| argenx SE ADR
ARGX
| LOCK|ZTLrWMN | LOCK|pb | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r^>!k@ | LOCK|Ys< | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|c>Xl!> | LOCK|m>!b | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|DHg^@ZBf | LOCK|D^BK | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|z>&%!G | LOCK|@? | $24B | |||
| Incyte Corp
INCY
| LOCK|M%!Q#X | LOCK|xn | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|mZlW>< | LOCK|MJW | $15B |
United States